Addex Therapeutics Ltd. SEC filings ADXN
Addex Therapeutics Ltd. has 279 filings in SEC EDGAR's recent list, going back to Sep 24, 2019. Its latest annual report, Form 20-F, was filed on May 15, 2026 for the period ended Dec 31, 2025. The most recent current report (Form 6-K) was filed on Oct 29, 2026. The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 424B5 | Prospectus supplement | Dec 10, 2025 | — |
| F-3 | Shelf registration (foreign issuer) | Nov 19, 2025 | — |
| 424B3 | Prospectus | Apr 24, 2024 | — |
| POS AM | Filing | Apr 18, 2024 | — |
| 424B5 | Prospectus supplement | Jan 30, 2024 | — |
| 424B3 | Prospectus | Nov 30, 2023 | — |
| POS AM | Filing | Nov 29, 2023 | — |
| 424B3 | Prospectus | Oct 23, 2023 | — |
| F-6 POS | Filing | Oct 6, 2023 | — |
| 424B3 | Prospectus | Aug 11, 2023 | — |
| POS AM | Filing | Aug 10, 2023 | — |
| S-8 | Employee stock plan registration | Jun 8, 2023 | — |
| 424B3 | Prospectus | Jun 2, 2023 | — |
| F-1/A | Form f-1/a | Jun 1, 2023 | — |
| F-1/A | Filing | May 11, 2023 | — |
| F-1 | Registration statement (foreign issuer) | May 3, 2023 | — |
| 424B5 | Prospectus supplement | Apr 4, 2023 | — |
| 424B3 | Prospectus | Nov 22, 2022 | — |
| 424B3 | Prospectus | Nov 16, 2022 | — |
| 424B3 | Prospectus | Aug 30, 2022 | — |
| POS AM | Filing | Aug 24, 2022 | — |
| F-1 | Registration statement (foreign issuer) | Aug 19, 2022 | — |
| 424B5 | Prospectus supplement | Jul 26, 2022 | — |
| 424B5 | Prospectus supplement | Jul 20, 2022 | — |
| POS AM | Filing | Mar 31, 2022 | — |
| POS AM | Filing | Mar 29, 2022 | — |
| 424B3 | Prospectus | Jan 19, 2022 | — |
| F-1 | Registration statement (foreign issuer) | Jan 7, 2022 | — |
| 424B5 | Prospectus supplement | Dec 20, 2021 | — |
| 424B5 | Prospectus supplement | Jun 30, 2021 | — |
| S-8 | Employee stock plan registration | Apr 8, 2021 | — |
| F-3 | Shelf registration (foreign issuer) | Apr 7, 2021 | — |
| 424B4 | Prospectus | Jan 8, 2021 | — |
| F-1/A | Filing | Jan 6, 2021 | — |
| F-1 | Registration statement (foreign issuer) | Dec 14, 2020 | — |
| POS AM | Filing | Apr 27, 2020 | — |
| 424B4 | Prospectus | Jan 28, 2020 | — |
| F-1/A | Filing | Jan 23, 2020 | — |
| F-1/A | F-1a | Jan 14, 2020 | — |
| F-6 | Filing | Dec 18, 2019 | — |
| F-1 | Registration statement (foreign issuer) | Dec 17, 2019 | — |
Showing 41 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ADXN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- Switzerland
- Headquarters
- Geneva, Switzerland
- SEC filer status
- Non-accelerated filer
- SEC CIK
- 1574232
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.